Jumia Technologies AG - ADR vs Eli Lilly And Co — how do they compare? Jumia Technologies AG - ADR trades at $6.45 (market cap $719.58M), while Eli Lilly And Co trades at $1,220.55 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 1500.9× Jumia Technologies AG - ADR's market cap, and Eli Lilly And Co pays a 0.57% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| JMIA | LLY | |
|---|---|---|
Market Cap | $719.58M | $1.08T |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $1.24K |
52-Week Low | $5.69 | $639.43 |
Enterprise Value | $666.68M | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.325, up 5.42% today, but technical indicators show a bearish trend with moving averages signaling sell. The company reported a net loss of $61.55 million in 2025, though revenue grew to $188.93 million and the net loss margin improved to -32.58%. Recent news highlights progress toward Q4 2026 breakeven and a $50 million capital raise.
The outlook remains speculative with persistent losses and high valuation ratios like P/B of 55.05, but analyst consensus is bullish with 71% buy ratings. Key risks include cash burn and competitive pressures, while catalysts include continued operating leverage and expansion initiatives.
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Trailing returns across standard periods
Latest headlines on both assets
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →